Cheelcare Reports Second Consecutive Month of Record Companion Bookings with April Bookings up 147% Year-over-Year and 38.5% Sequentially
Cheelcare extends its booking streak as Companion reimbursement catalyst takes hold, but the Curio regulatory journey and thin balance sheet keep risk elevated.
On May 11, 2026, Cheelcare reported a second consecutive month of record Companion power‑assist bookings. April bookings rose 147% year‑over‑year and 38.5% sequentially from March. Request‑for‑quotation (RFQ) activity surged 64% compared to March and has more than doubled since January. Management attributed the acceleration to the Medicare/Medicaid reimbursement eligibility obtained in January 2026, which is expanding insurance‑funded access and reducing reliance on private‑pay purchases. The company also highlighted its presence at key industry expos.
The announcement is positive but expected. Cheelcare’s prior release on April 9 already disclosed record Companion sales in March and the first commercial delivery of its Curio robotic wheelchair. The May news simply extends that sequential momentum while adding granularity on RFQs. No new strategic milestone—such as a major regulatory clearance or a transformative partnership—is introduced. The reimbursement tailwind was already well understood by the market after the January Medicare/Medicaid approval, and the stock had already rallied sharply on that news (from ~$0.87 to $1.98). The current booking data confirms the thesis but does not materially alter the risk/reward profile. Therefore, the release qualifies as Routine – Positive.
Cheelcare Inc. is a medical‑device company focused on powered mobility solutions for individuals with disabilities. Its flagship product is Curio, a robotic complex‑rehab power wheelchair designed to offer advanced functionality and independence. The company also sells the Companion, a compact power‑assist unit that attaches to manual wheelchairs, which serves as a lower‑cost entry point and has generated the bulk of recent sales momentum. Cheelcare operates a 16,000‑sq‑ft manufacturing facility in the U.S. and sells through a network of more than 500 dealers globally, including partnerships with the top three North American distribution networks and over 20 U.S. Veterans Affairs Medical Centers. The company is listed on the TSX Venture Exchange.